AGEN : NASDAQ : Health Care
$3.45 | %
Today's Range: 3.42 - 3.52
Avg. Daily Volume: 1016400.0
05/26/17 - 4:00 PM ET

Financial Analysis


AGENUS INC's gross profit margin for the first quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth.

At the same time, stockholders' equity ("net worth") has significantly decreased by 79.96% from the same quarter last year.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY17 Q1 FY16
Net Sales ($mil)26.965.96
EBITDA ($mil)0.0-27.07
EBIT ($mil)-13.45-28.31
Net Income ($mil)-17.1-31.78


Balance Sheet Q1 FY17 Q1 FY16
Cash & Equiv. ($mil)123.82148.23
Total Assets ($mil)203.27221.14
Total Debt ($mil)0.0118.31
Equity ($mil)8.9144.45


Profitability Q1 FY17 Q1 FY16
Gross Profit Margin-49.91-454.24
EBITDA Margin0.0-454.23
Operating Margin-49.91-475.11
Sales Turnover0.210.12
Return on Assets-55.25-45.63
Return on Equity-1263.59-227.48
Debt Q1 FY17 Q1 FY16
Current Ratio0.05.17
Debt/Capital0.00.73
Interest Expense0.04.13
Interest Coverage0.0-6.85


Share Data Q1 FY17 Q1 FY16
Shares outstanding (mil)87.886.53
Div / share0.00.0
EPS-0.18-0.37
Book value / share0.10.51
Institutional Own % n/a n/a
Avg Daily Volume1132894.01143171.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 35.60 indicates a significant premium versus the S&P 500 average of 3.00 and a significant premium versus the industry average of 9.84. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, AGENUS INC proves to trade at a premium to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
AGEN NM Peers 39.69   AGEN NA Peers 41.03

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

AGEN's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.

Ratio not available.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
AGEN NM Peers 23.10   AGEN NA Peers 0.48

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

AGEN's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
AGEN 35.60 Peers 9.84   AGEN -3.22 Peers -13.13

Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

AGEN is trading at a significant premium to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

AGEN is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
AGEN 7.27 Peers 108.22   AGEN 62.43 Peers 462.39

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

AGEN is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

AGEN significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades